Among 69,221 propensity-matched patients with IBD, those who had received a GLP-1 RA had a 5-year colorectal cancer incidence of 0.2% compared with 0.42% in non-GLP-1 RA users (OR, 0.49), corresponding to a 51% reduction in odds of developing colorectal cancer
How long a medication stays on the monitoring list can vary depending on the medication, its effect, and how widely its being used
Doxorubicin: an overview of the anti-cancer and chemoresistance mechanisms
Dermatologic Common (1% to 10%): Hair loss, rash, urticaria Postmarketing reports : Alopecia, angioedema, rash, urticaria Hair loss was reported in up to 5.8% of treated patients vs 1% placebo, with higher incidence associated with greater weight loss (20% or more)
Analysts anticipate strong sales for Retatrutide, with Eli Lilly's market position strengthening